Neisseria gonorrhoeae

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

Retrieved on: 
Thursday, February 29, 2024
Mycobacteroides abscessus, Urinary tract infection, Neisseria gonorrhoeae, Pyelonephritis, MCRI, Escherichia coli, Recce, RCE, Murdoch, Health, Streptococcus pneumoniae, Bacteria, ASX, AIR, Global Health, Organization, Partnership, Pharmaceutical industry

In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.

Key Points: 
  • In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.
  • “The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance.”
    The collaboration between Recce’s AIR Unit and MCRI exemplifies the power of partnership in driving medical breakthroughs.
  • As both organizations work together to advance anti-infective research, they remain committed to improving patient outcomes and addressing global health challenges.
  • James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research.

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Tuesday, January 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems

Retrieved on: 
Monday, January 8, 2024
Dicarboxylic acid, Food, FDA, QGEN, QIAGEN, Real-time polymerase chain reaction, Infection, DNA, PCR, Genetically modified bacteria, STI, Chlamydia trachomatis, Neisseria gonorrhoeae, Diagnosis, Senior

The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.

Key Points: 
  • The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.
  • This FDA clearance supports the test menu expansion for NeuMoDx Molecular Systems in the U.S.
  • The systems extract DNA to isolate the target nucleic acids and then conduct a real-time polymerase chain reaction (RT-PCR).
  • For more information about the NeuMoDx assay menu, please visit https://go.qiagen.com/neumodx

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea

Retrieved on: 
Monday, December 18, 2023
ASX, RCE, Risk, WHO, Ageing, Vaginitis, Mouse, Gonorrhea, Infection, Neisseria gonorrhoeae, Azithromycin, World Health Organization, Safety, Ceftriaxone, Vaccine

“The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • After three days, the mice treated with R327 showed an approximate 4-log (99.99%) reduction in bacterial shedding, demonstrating significant bactericidal activity.
  • After five days of treatment, R327 showed a 3.5-log (>99.9%) reduction in bacterial shedding compared to the placebo-treated group.
  • A late-stage preclinical study comparing IV administration to a topical application of R327 against N. gonorrhoeae is underway.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

GeneProof Announces Expansion of its IVDR-Certified PCR Portfolio

Retrieved on: 
Tuesday, October 3, 2023
Ureaplasma urealyticum, CT, IVDR, Urinary tract infection, Workflow, CP, Infection, Neisseria gonorrhoeae, Chlamydia trachomatis, Real-time, Quality management system, Mycoplasma genitalium, Mycoplasma hominis, NG, Canine vector-borne disease, Diagnosis, PCR, Chlamydia pneumoniae, Medical device, Telecommunications, Ureaplasma, EU, Mycoplasma, Chlamydia

BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.

Key Points: 
  • BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.
  • This comes as a testament to the company's dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027.
  • Currently, 27 products are IVDR cleared, with 16 that are Notified Body certified in class C and B.
  • GeneProof was among the first to obtain the EU Certificate for Quality Management System under the new Regulation (EU) 2017/746 IVDR.

Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress

Retrieved on: 
Wednesday, September 6, 2023
Infectious Diseases, Pharmaceutical, Health, Methicillin-resistant Staphylococcus aureus, Infection, COVID-19, Neisseria gonorrhoeae, AMR, Associate, CDC, Business development, Division, Bacteria, Vaccine, Antibiotics, Science, Debiopharm

Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.

Key Points: 
  • Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
  • Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund.
  • *
    “It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm.
  • Along with products that will reduce the degree of colonization (i.e.

“Gonorrhea Alert” Intensifies Globally, says AHF

Retrieved on: 
Wednesday, July 26, 2023
Public Policy, Government, Pharmaceutical, AIDS, Health, Infectious Diseases, Communications, Social Activism, Advocacy Group Opinion, Infection, AHF, STI, Neisseria gonorrhoeae, Gonorrhea, Multimedia, HIV, AIDS Healthcare Foundation, Syphilis, World Health Organization, Disease, Vaccine, Birth control, Neisseria

Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.

Key Points: 
  • Neisseria gonorrhea is exceptionally dangerous due to its resistance to multiple treatments, including new antibiotics being developed specifically for this pathogen.
  • “Condoms are still the most cost-effective way to prevent gonorrhea, syphilis, and other STIs, including HIV – a fact people everywhere should be made aware of.
  • That starts with information campaigns at all levels of government in all countries and ensuring adequate access to free or affordable condoms.
  • Over 82 million new cases of Neisseria gonorrhea are reported in adults between the ages of 15 to 49 annually, according to the World Health Organization.

New Research Shows Promising Possibilities for At-Home Testing to Detect Sexually Transmitted Infections

Retrieved on: 
Tuesday, July 25, 2023
Vagina, Laboratory, Kaiser Permanente, Human papillomavirus infection, STI, Urine, Infection, Los Angeles County Department of Health Services, Research, Temperature, Neisseria gonorrhoeae, Doctor of Philosophy, Centers for Disease Control and Prevention, Chlamydia trachomatis, Public health, Rectum, Cervical cancer, Los Angeles County Department of Public Health, Physician, HPV, Patient, Throat, Birth control, Mineral oil, Neisseria, Chlamydia

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. These findings could enable discreet new testing options that expand access to screening.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Self-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs), according to research presented today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.
  • However, more research is needed to establish the reliability of self-collected tests.
  • For 15 study participants, the researchers evaluated 5 self-collected swabs to assess variability in swabs taken from the same individual.
  • The researchers were motivated to increase inclusivity and access to STI testing by exploring additional options for self-collection and home testing.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”